1. Endothelial-cell-mediated mechanism of coronary microvascular dysfunction leading to heart failure with preserved ejection fraction
   Yong Wang et al, 2022, Heart Failure Reviews CrossRef
2. Gut microbiota: A new therapeutic target for diabetic cardiomyopathy
   Suxin Yuan et al, 2022, Frontiers in Pharmacology CrossRef
3. Human Relaxin-2 (Serelaxin) Attenuates Oxidative Stress in Cardiac Muscle Cells Exposed In Vitro to Hypoxia–Reoxygenation. Evidence for the Involvement of Reduced Glutathione Up-Regulation
   Silvia Nistri et al, 2020, Antioxidants CrossRef
4. Relaxin inhibits 177Lu-EDTMP associated cell death in osteosarcoma cells through notch-1 pathway
   Junhua Xu et al, 2022, Acta Pharmaceutica CrossRef
5. The Melanocortin MC5R as a New Target for Treatment of High Glucose-Induced Hypertrophy of the Cardiac H9c2 Cells
   Maria Consiglia Trotta et al, 2018, Frontiers in Physiology CrossRef
6. Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes
   Hooi Hooi Ng et al, 2018, Frontiers in Pharmacology CrossRef
7. Activating Cannabinoid Receptor 2 Protects Against Diabetic Cardiomyopathy Through Autophagy Induction
   Aiping Wu et al, 2018, Frontiers in Pharmacology CrossRef
8. Targeting G protein‐coupled receptors for heart failure treatment
   Bui San Thai et al, 2023, British Journal of Pharmacology CrossRef